Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

While 2025 remains an unknown quantity, it’s clear that fundraisers and investors see the value in visiting London in ...

Sports marketing offers healthcare brands an alternative channel to reach their audiences and align with the strong brand ...

The purchase price of the facility was not disclosed, but Lilly says its new $3 billion investment – part of $23 billion ...

Agamree was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in January and has a pre-discount list ...

Private equity group Carlyle has joined forces with other investors on a €900 million-plus recapitalisation of UK drugmaker ...

Advance Best-In-Class Treatment Across CNS, Emergency Use Treatments, & Infectious Diseases & Secure Long-Term Funding in ...

A new study has confirmed that the rate of colorectal cancer is rising in younger adults around the world, with England among ...

Read Deep Dive: AI 2024 in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, ...

As a result of the preliminary STOMP data – which gave the chances of a positive outcome from the study at less than 1% – the ...

The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for medicines that it says have added around $815 million to US drug spending.

Mulvany – who left BenevolentAI when it listed on the Amsterdam stock exchange in 2022 and retains a sizeable stake in the ...